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INTRODUCTION
Cervical cancer is one of the diseases 
with a very high mortality rate (Gonzalez et 
al., 2005). The causes of cervical cancer is 
a Human papillomavirus (HPV) infection. 
WHO reported that two types of HPV virus-
es that widely identified as attacker type 16 
and 18 (WHO, 2019). Potential effort to solve 
cervical cancer is vaccinations. According 
to Bruni et. al. (2019) 94% cases of cervical 
cancer in Indonesia are caused by type 16 of 
HPV, Thus during the development of cervi-
cal cancer, type 16 of HPV is the most poten-
tial target.
The most efficient method of develop-
ing vaccines is through the immunoinformat-
ics method. The success of immunoinformat-
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ics methods has been proven (Li et al., 2015). 
The process of developing vaccines through 
immunoinformatics methods is by predicting 
the bond strength between the peptides of vac-
cine candidate from the protein of microorgan-
ism with the Major Histocompatibility Com-
plex (MHC) proteins (MHC I and MHC II) 
(Taupiqurrohman et al., 2016). This is based 
on the mechanism of immune system activa-
tion that passes through the protein. Peptides 
that are strongly bound to MHC I will be able 
to activate cytotoxic T cells, while peptides 
that are strongly bound to MHC II will acti-
vate T helper cells. The next step of immune 
response after activation of cytotoxic T cells 
is the degradation of infected cells by these T 
cells while activated helper T cell antibodies 
will be formed (Sompayrac, 2008). Therefore, 
the prediction of peptide-MHC I and II inter-
actions needs to be done in the process of find-
ing peptide vaccine candidates. The prediction 
process involves binding affinity as an indica-
tor. Affinity is the tendency of a substance to 
bind to another substance (Kim et al., 2012).
To obtain accurate bond predictions, 
three-dimensional visualization of interac-
tions between the peptide and MHC I and 
II is required. Visualization of the three-di-
mensional structure of interactions between 
peptides and MHC or with other proteins is 
still limited to the crystal structure. Currently, 
computer programs are developed to predict 
the interaction of peptides-protein visually. 
The prediction method is known as molecular 
docking. This method develops along with the 
need to understand the important role of pro-
teins in body cells. The protein visualization 
by molecular docking is needed to understand 
the role protein easier, as the results of the 
conventional molecular method are still lim-
ited (Kurcinski et al., 2015).
The vaccine developed through immu-
noinformatics must not have the similarity 
of genes or genomes between microorgan-
isms where the vaccines will be developed 
with the human genome. This is to avoid the 
emergence of autoimmune diseases after vac-
cination. In the process of obtaining a vaccine 
candidate using the immunoinformatics meth-
od, it is protein from a vaccine source micro-
organism that being utilized, not the gene. 
However, it is important to examine the genes 
of candidate vaccine source microorganisms 
with the human genome (Taupiqurrohman et 
al., 2016).
All of HPVs, including type 16, have 
genomes which are divided into three main 
regions, namely the regulator, the late and the 
early. The late region is divided into two main 
parts namely Late 1 and Late 2 which are re-
sponsible for the formation of the viral capsid. 
While early is divided into seven parts, name-
ly Early 1, Early 2, Early 3, Early 4, Early 
5, Early 6 and Early 7 which are responsible 
for mastering and causing cancer in the host 
(Morshed et al., 2014). All genes in HPV pro-
duce the same name as the gene name. Sup-
pose the Early 1 gene produces protein Early 
1 and so on.
Early 4 genes HPV has a role in ad-
vanced infections when virions are made. 
These genes play an important role in matura-
tion (viral maturation) and replication. Early 
4 protein also affects cytoplasmic decay in cy-
tokeratin tissue in human keratinocyte cells. 
Based on its function adjacent to cancer-caus-
ing genes in cervical cancer, it is necessary to 
test the Early 4 genes as a source of vaccine 
candidates. The aim of this study was to carry 
out testing of the Early 4 protein of type 16 
HPV through immunoinformatics methods as 
an effort to get a peptide vaccine candidate for 
cervical cancer.
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MATERIALS AND METHODS
The tools used are a personal comput-
er with specifications of the Intel® Celeron® 
CPU N3060@1.60 GHz, 4.00 GB RAM, 64 Bit 
System Operations, and 250 GB Hard disks.
The research material consisted of a 
sequence of amino acid E4 protein, web-
based software workbench, IEDB-AR, 
CABSdock, and standalone software Ac-
celrys Study Discovery 4.5, the sequence 
of amino acid peptide as control peptides 
from MHC I and II crystal structures, ob-
tained from protein data bank (PDB) website.
Research Procedure
The research was carried out using a 
computational method with the following pro-
cedure, the amino acid sequence data of early 
4 protein of HPV type 16 was compiled from 
the UniProt website. Furthermore, the protein 
homology process was carried out with the 
entire human genome in the workbench web-
site (Fatima & Desu, 2014). After the homol-
ogy process was carried out, the MHC I and 
MHC II crystal structures were downloaded 
from the website http://www.rcsb.org.
The next step was to predict the se-
quence of the Early 4 protein of type 16 HPV 
to get cervical cancer peptide vaccine can-
didate. The prediction process was carried 
out using IADB-AR software. The principal 
works were to look for sequences of peptides 
from Early 4 proteins that are strongly bound 
to MHC I and II. This software uses consen-
sus algorithms with affinity energy values as 
an indicator (Kim et al., 2012).
While waiting for the prediction pro-
cess, the process of downloading the MHC I 
and II crystal structures was carried out from 
http://www.rcsb.org (PDB code 2BNQ for 
MHC I and 1J8H for MHC II) and peptide 
separation was attached to the MHC I and 
MHC II crystal structures using Accelrys Dis-
covery Studio 4.5.
The next step was the molecular dock-
ing. The purpose of this step was to visual-
ize the interaction between vaccine candidate 
peptides and MHC I and II. The molecular 
docking process was divided into two stag-
es, namely the first process was validating 
CABSdock software by doing docking be-
tween peptides that have been separated from 
crystal structures by MHC I and II. The result 
is categorized as valid if it has an RMSD val-
ue below 3 (Kurcinski, et. al., 2015). The sec-
ond process was molecular docking processes 
between peptides candidate using CABSdock 
software. The last step was the process of ana-
lyzing molecular docking results with Accel-
rys Discovery Studio 4.5 software.
RESULTS AND DISCUSSION
The Sequence of Early 4 Protein
Table 1 shows the sequence of amino 
acids from the early 4 protein of type 16 HPV. 
These proteins are composed of 94 amino ac-
ids.
The Homology Process of Early 4 Protein 
with the Human Genome
Based on the process in the website 
http://workbench.sdsc.edu/, the Early 4 pro-
tein do not have similarities/identities with 
the human genome as it produces an identical 
percentage of 0%. This process is intended 
so that the resulting vaccine does not trig-
ger an autoimmune response. Autoimmune 
is a specific immune response disorder that 
attacks the healthy cells, so if a peptide vac-
cine sourced from a protein similar to humans 
it might result in this response. The autoim-
mune response is usually induced by T cells 
and B cells respectively, or it can be by both. 
In some cases, autoimmune can result in loss 
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Gene Sequence
E4 YYVLHLCLAATKYPLLKLLGSTWPTTPPRPIPKPSPWAPKKHRRLSS
DQDQSQTPETPATPLSCCTETQWTVLQSSLHLTAHTKDGLTVIVTLHP
Table 1. The sequence of Amino Acids E4 Protein HPV type 16
(Source: http://www.uniprot.org)
of body tissue function (Bellone, 2005).
Download MHC I and MHC II Crystal 
Structures
The download process of MHC I and II 
crystal structures was carried out through the 
protein database website, http://www.rcsb.org 
or protein data bank (PDB). The PDB code 
used for MHC I is 2BNQ and 1J8H for MHC 
II (Taupiqurrohman, 2016).
Prediction of the Amino Acid Sequence of 
Candidate Vaccine Peptides
MHC I-Peptide
The prediction was carried out using 
IEDB-AR (Vita et al., 2010) by utilizing ami-
no acid sequences of E4 HPV type 16 pro-
teins. IEDB-AR was the result of the develop-
ment of the IEDB.
IEDB-AR works by using a consensus 
algorithm (SMMPMBEC and NetMHCpan). 
This algorithm was developed on the grounds 
that the combination method can produce 
the predictions that are far better than using 
a single method. In the process of predicting 
vaccine candidates, the algorithm produces a 
percentile score. Percentile scores are defined 
as the percentage of random peptides from the 
E4 protein bound to the MHC. The use of a 
consensus approach will result in a bond af-
finity score for peptides in the form of a me-
dian percentile score from different predictors 
(Kim et al., 2012). Table 2 and 3 is the result 
of IEDB-AR prediction. Amino acid sequence 
Lysine, Lysine, Valine, Glycine, Serine, Thre-
onine, Tryptophan, Proline, and Threonine 
(KLLGSTWPT) is a predictive peptide vac-
cine candidate that can activate cytotoxic T 
cells (Table 2).
Allele
Location of
Sequence Long Peptide ScorePercentile
IC50 (M)
Start End ann SMM Comblib
HLA-A*02:01 17 25 9 KLLGSTWPT 0.6 6 47.55 9.02 x 10-6
Tabel 2. Prediction of candidate vaccine peptide sequences based on their bond with MHC I
Allele
Location of 
Sequence
Long Peptide Score Percentile
IC50 (M)
Start End Comb.blib smm nn
HLA-
DRB1*01:01
1 15 15 YYVLHLCL
AATKYPL
6,39 0,01 62 11,6
Tabel 3. Prediction of candidate vaccine peptide sequences based on their association with MHC II
Jurnal Biodjati 4(2):252-262, November 2019 256
Jurnal Biodjati 4(2):252-262, November 2019
http://journal.uinsgd.ac.id/index.php/biodjati
Selection of candidate vaccines (pep-
tides) is based on the value of the smallest 
percentile score. The smaller the percentile 
score the better the bond (Kim et al., 2012). 
The percentile score is a term that refers to the 
percentage score that is equal to or less than 
the given value, in this case, the intended value 
is the inhibitor concentration 50 (IC50) value.
Inhibitor Concentration 50 (IC50) is a 
50% concentration of the part of the peptide 
bound to MHC. This binding (energy) capa-
bility can be described as the ratio between 
standard IC50 peptides and test peptides (Sette 
et al., 1994). Determination of IC50 values in 
this software uses the consensus algorithm 
method, which is a combination of ANN (Ar-
tificial Neural Network) algorithm, Stabilized 
Matrix Method (SMM) and Comblib (Combi-
natory Library) algorithm. ANN is a computer 
algorithm that mimics the work of the brain 
system. ANN consists of a collection of sim-
ple units that form communication networks 
like neurons in the brain. The unit will respond 
if there is an input signal. The unit referred in 
this algorithm is an amino acid residue from 
MHC I. While the signal is a protein residue 
(peptide) which will be predicted in this case 
E4 protein with a response in the form of the 
IC50 value generated (Fleri, 2012).
Stabilized Matrix Method is a meth-
od for calculating the affinity peptide matrix 
bound to MHC (Fleri, 2012). Whereas com-
binatory library is an affinity measurement 
method from a combination of various pep-
tides (protein residues tested) against MHC. 
The three methods work together to produce 
better accuracy. Furthermore, the value pro-
duced by each method is ranked and a percen-
tile score is generated.
MHC II-Peptide
The amino acid sequence of Tyrosine, 
Tyrosine, Valine, Leucine, Histidine, Leu-
cine, Cysteine, Leucine, Alanine, Alanine, 
Alanine, Threonine, Lysine, Tyrosine, Pro-
line, and Leucine (YYVLHLCLAATKYPL) 
are candidate predictive peptides of vaccines 
that can reactivate Helper T cells. (Table 3).
Determination of IC50 peptide-MHC 
II had similarities with the peptide-MHC I 
which used a consensus algorithm consisting 
of NN-align (Neural Network Alignment), 
SMM-align (Stabilization Matrix Alignment 
Method), and Comb.blib (Combinatory Li-
brary). The choice of this consensus method 
is recommended by the IEDB-AR program in 
the predisposing process.
NN-align is an algorithm compiled to 
predict MHC II peptide bonds with the same 
principle as ANN. The NN-align is able to 
predict the affinity of peptides against MHC 
II, and identify binding-core peptides, namely 
peptide fragments that interact with the main 
bonding sac of MHC II (binding groove). 
While SMM-align is a method of predicting 
MHC II-peptide bonds from certain peptide 
sequence patterns based on the matrix (Po-
sition-Specific Weight Matrix). The result 
of the SMM-align method is IC50. While the 
comb.lib method uses a peptide position scan-
ning approach in a positional scanning com-
binatorial libraries to systematically pool ran-
dom peptides to determine the contribution of 
each amino acid per nine peptide positions to 
MHC II peptide bonds. Each pool contains 9 
mer peptides with one residue remaining in 
one position. Each residue of 20 natural ami-
no acids is in the main chain of 9 mer, so the 
entire database contains 180 mixed peptides. 
Competitive binding assays were carried out 
to determine IC50 values for each pool. The 
final result of this method is the prediction of 
new 9 mer peptide bonds from 20 score ma-
trices against MHC II (Fleri, 2012). As in the 
prediction of MHC-peptide I, the IC50 value 
generated by each method was then ranked 
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and the result is a percentile score. A small 
percentile score indicates that the IC50 value 
generated by these methods is possessed by a 
small number of peptide sequences of type 16 
EV HPV proteins that are predicted, therefore 
the smaller the percentile score the stronger 
the bond.
Separation of Peptide-MHC Crystal Struc-
tures
The separation between MHC peptides 
(MHC I and MHC II) on MHC I and MHC II 
crystal structures has been downloaded from 
the database using Accelrys Discovery Studio 
4.5 (Figure 1).
Figure 1. Result of Separation of MHC by Using Accelrys Discovery Studio
No Kode PDB(Crystal structure) RMSD (Å) A sequence of peptide crystal structure
1 2BNQ 0.85 SLLMWITQV
2 1J8H 1.55 PKYVKQNTLKLAT
Table 4. Results of Validation of CABSdock Software
Molecular Docking
Validation of CABSdock Software
Validation was carried out to find out 
the quality of the software method used. 
The quality assessment was based on the 
results of repeating an MHC-peptide com-
plex found in PDB by the selected software. 
The method was categorized as good if the 
docking results have a value of intersection.
The value intersection was showed by root 
mean standard deviation (RMSD) value. 
RMSD value is a value that describes the posi-
tion of the ligand at the receptor after reassem-
bling using the molecular docking method.
According to Kurcinski et al. (2015) that 
RMSD value below 3 Å showed a good or 
No Gene Peptide VaccineCandidate
PDB Receptor Energy of Interaction
MHC I
(Allele 
HLA-A*02:10)
MHC II
(Allele HLA-
DRB1*01:01)
Peptide Vaccine 
Candidate
(Kcal/mol)
Peptide Control
(Kcal/mol)
1 E4 KLLGSTWPT 2BNQ - - 121.00 - 192.80
2 E4 YYVLHLCLAATKYPL - 1J8H -204.80 -185.40
Table 5. Information on molecular docking energy results
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valid docking method. Table 4 showed the re-
sult of CABSdock software validation. Based 
on the result, CABSdok is a valid method be-
cause the RMSD value is below 3 Å, which is 
0.85 - 1.55 Å.
Docking Peptide of Vaccine Candidate with 
MHC I and II
The CABSdock software produced 10 
conformational predictions with each confor-
mation having 1000 conformational approach-
es. Each conformational prediction produces 
different energy interactions with each other. 
What is displayed in the table is the interac-
tion energy with the best conformation. The 
interaction energy produced by CABSdock 
is the accumulation of Columb and Linneard 
Jones interactions. The calculation process is 
carried out during the molecular tethering pro-
cess (Blaszczyk et al., 2016). Table 5 shows 
the energy of molecular docking results be-
tween vaccine candidate peptides and MHC 
with control (crystal structure).
Conformation Analysis of Molecular Dock-
ing Results
Conformations of Peptide Vaccine Candi-
date with MHC I
The energy affinity value resulting 
from the molecular docking process against 
peptides vaccine candidate with MHC I was 
higher than the crystal structure affinity ener-
gy (2BNQ) which are 121.00 Kcal/mol and 
192.00 Kcal/mol, respectively. This value 
indicates that the interaction in the confor-
mation of peptide vaccine candidate-MHC I 
is relatively lower (not strong) compared to 
the control (crystal conformation). However, 
in terms of the location of the peptide bound 
to MHC I, the peptide vaccine candidate has 
the same area as the crystal structure peptide 
(Figure 2).
Based on the results of the analysis 
using the Accelrys Discovery Studio in the 
conformation of the MHC I-peptide vaccine 
candidate a conventional hydrogen bond was 
formed between amino acid residues 77ASP-
189THR with a distance of 3.28 Å. The in-
teraction of carbon-hydrogen with the amino 
acid 66 LYS-184GLY with a distance of 3.63 
Å was also formed A hydrogen donor inter-
action was also formed between the amino 
acid 167TRP-181LYS at a distance of 3.27 
Å. Meanwhile, in the control conformations 
of, only conventional hydrogen bonds were 
formed, namely between the amino acids 
97ARG-183 Leu with distance 2.68 Å, and 
26GLY-189VAL with a distance of 3.13 Å 
(Figure 3).
In Figure 4, there was a hydrophobic 
interaction formed in the conformation of 
MHC I-peptide vaccine candidate involving 
pi-electron donors The interaction formed 
between the amino acid 147TRP-187TRP 
at a distance of 4.60 Å, 99TYR-182LEU at 
a distance of 5.32 Å, 114HIS-188PRO at 
a distance of 3.92 Å, 147TRP-188PRO at a 
distance of 4.88 Å, 167TRP-181LYS at a dis-
tance of 5.43 Å, 156LEU-187TRP at a dis-
tance of 3.31, 126 LEU-187TRP at a distance 
of 4.71 Å, 153ALA -187TRP at a distance of 
5.33 Å, 33PHE-181LYS at a distance of 4.76 
Å and 156LEU-187TRP at a distance of 3.89 
Å. In addition, there were also Alkyl interac-
tions between 66LYS-183LEU at a distance 
of 3.95 Å, 184CYS-182LEU at a distance of 
4.10 Å, 5MET-181LYS at a distance of 4.76, 
and 124ILE-188PRO at a distance of 4.62 Å.
Figure 4 also shows, the formation of 
an interaction involving pi-electron donor and 
sigma-pi between 33PHE-189VAL acid with 
a distance of 3.91 Å, 99TYR-184MET with 
a distance of 4.11 Å, 114HIS-182LEU with 
a distance of 4.49 Å, 114HIS-184MET with 
a distance of 3.67 Å, 116TYR-182LEU with 
a distance of 5.34 Å, 147TRP-182LEU with 
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Figure 2. Result of Molecular Docking of Pep-
tide-MHC I (Red = Control Peptide; Green 
= Predicted Peptides)
Figure 3. Hydrogen Bonds Formed between Prediction 
of Peptide-MHC I (Red = Control Peptide; 
Green = Predicted Peptides)
Figure 4. Hydrophobic Interaction Formed between 
Prediction of Peptide-MHC I (Red = Con-
trol Peptide; Green = Predicted Peptides)
Figure 5. Electrostatic Interaction Formed between 
Prediction of Peptide-MHC I (Red = Con-
trol Peptide; Green = Predicted Peptides)
a distance of 4.82 Å, 167TRP-18ILE with a 
distance of 5.41 Å, 171TYR-189VAL with 
a distance of 5.06 Å, 66LYS-185TRP with 
a distance of 4.70 Å, and 66LYS-185TRP 
4.66 Å in control conformation. In addition, 
there was an alkyl interaction between the 
5MET-186ILE amino acids, 28VAL-189VAL, 
124ILE-182LEU, 156LEU-184MET, 
160LEU-184MET, 164CYS-186ILE and 
5MET-189VAL with a distance of 4.52 Å, 
4.44 Å, 4, 50 Å, 3, 86 Å, 4.82 Å, 4.08 Å, 4.77 
Å respectively.
Figure 5. shows a salt bridge formed 
between amino acids 97ARG-189THR with 
a distance of 2.77 Å, 63GLU-181LYS with a 
distance of 3.71 Å, and 63GLU-181LYS with 
a distance of 3.74 Å. In addition, there is an 
interaction between the 167TRP-181LYS at 
a distance of 3.27 Å and interaction between 
the 116TYR-189THR at a distance of 4.02 
Å in the conformation of the MHC I-peptide 
vaccine candidate. Meanwhile, in the control 
confirmation, there is only a load interaction 
extract which is formed between amino acid 
SER181-ASP77 at a distance of 5.00 Å.
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Conformations of Peptide Vaccine Candi-
date with MHC II
Based on Table 5, the energy affinity 
values resulting from the molecular docking 
process of the conformations MHC II-peptide 
vaccine candidate was lower (-204.80 Kcal/
mol) than the control (crystal structure) affin-
ity energy, which was -185.40 Kcal/mol. This 
value indicates that the interaction in the MHC 
II-peptide vaccine candidate conformations is 
stronger than the control conformation. In ad-
dition, the peptide vaccine candidate also lies 
on the same active site as the crystal peptide 
(Figure 6).
The Figure 7 shows in the conforma-
tions of MHC II-peptide vaccine candidate 
two hydrogen bonds are formed, namely be-
tween the amino acid 371THR-61ASN with 
distance 3.28 Å, and 372LYS-61ASN with 
distance 3.53 Å. While the conformations 
of the control forms eight hydrogen bonds, 
namely between the 68ASN-368THR residue 
within 2.76 Å, 366GLN-206ASP within 3.01 
Å, 373THR-68ASN within 3.65 Å (hydrogen 
carbon interaction), 249LYS-363TYR at 3.23 
Å (hydrogen carbon interaction), 365LYS-
206ASP runs 3.20 Å (hydrogen carbon inter-
action), 363TYR-204PHE is 3.95 (donor pi), 
365LYS-208TYR is 4.20 Å (pi donor) and 
367ASN-239TRP is 3.67 Å (donor pi).
Figure 8 show the result of hydropho-
bic interaction analysis on MHC II- peptide 
vaccine candidate conformations and control 
conformation. In MHC II-peptide vaccine 
candidate conformation, interactions occur 
between amino acids 375LEU-238TYR with 
a distance of 3.75 Å (pi sigma interaction), 
365HIS-256TYR with a distance of 3.95 Å 
(pi-pi interaction), 191HIS-365HIS at 4.93 Å 
(interaction of pi form T), 189VAL-372LYS is 
4.47 Å (alkyl interaction), 369ALA-245LEU 
4.77 Å (alkyl interaction), 370ALA-249LYS 
is 3.94 Å (alkyl interaction), 191HIS-ALA370 
spaced 5.46 Å (pi alkyl interaction), 239TRP-
369ALA 4.90 Å (pi alkyl interaction), 
363VAL-31PHE is 3.76 Å (pi sigma interac-
tion), 364LEU-53PHE is 3.57 Å (pi sigma in-
teraction), 68ASN-373TYR is 5.03 (pi amide 
interaction), 51ALA-363VAL is 4.57 Å (alkyl 
interaction), 64 VAL-372LYS border is 4.23 
Å (alkyl interaction), 21PHE-364LEU is 4.70 
(pi alkyl interaction), 23PHE-363LEU is 4.53 
(pi alkyl interaction), 373TYR-64VAL is 4.85 
Å (alkyl pi interaction), and 373TYR-67ALA 
is 5.00 Å (alkyl pi interaction).
Meanwhile in the control conformation, 
a hydrophobic interaction was formed be-
tween amino acid residues 189VAL-364VAL 
with a distance of 4.65 Å (interaction of 
alkyl), 189VAL-365LYS within 5.20 Å (alkyl 
interaction), 208TYR-365LYS within 4.62 
Å (interaction alkyl pi), 238TYR-372ALA 
is 4.01 Å (pi alkyl interaction), 239TRP-
365LYS is 4.70 Å (alkyl pi interaction), 
256TYR-362LYS is 5.31 Å (alkyl pi interac-
tion), 363TYR-252ALA is spaced 4.25 Å (pi 
alkyl interaction), 58ALA-361PRO is 4.36 Å 
(alkyl interaction), 64VAL-371LEU is 5.26 Å 
(alkyl interaction), 21PHE-361PRO is 4.17 Å 
(alkyl pi interaction) and 31PHE-361PRO is 
4.73 Å (alkyl pi interaction).
The conformations of MHC II-peptide 
vaccine candidate produced electrostatic in-
teractions in the form of a salt bridge between 
amino acids 372LYS-65ASP as far as 3.00 Å, 
75ARG-375LEU as far as 4.69 Å and interac-
tion of attractive charges between amino ac-
ids 372LYS-10GLU as far as 4.33 Å (Figure 
9). Whereas in the control conformation the 
electrostatic interaction was formed between 
the amino acid 365LYS-235ASP within 3.75 
Å (salt bridge), 365LYS-208TYR within 4.20 
Å and 365LYS-215TYR within 4.55 Å (inter-
action).
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Figure 6. Result of Molecular Docking of Pep-
tide-MHC II (Red = Control Peptide; 
Green = Predicted Peptides)
Figure 7. Hydrogen Bonds Formed between Prediction 
of Peptide-MHC II (Red = Control Peptide; 
Green = Predicted Peptides)
Figure 9. Electrostatic Interaction Formed between 
Prediction of Peptide-MHC II (Red = Con-
trol Peptide; Green = Predicted Peptides)
Figure 8. Hydrophobic Interaction Formed between 
Prediction of Peptide-MHC II (Red = Con-
trol Peptide; Green = Predicted Peptides)
ACKNOWLEDGMENTS
Many thanks to the UNPAD computa-
tional laboratorium team, who help with this 
research.
REFERENCES
Bellone M. (2005). Autoimmune Disease: 
Pathogenesis. Italy: John Wiley & Sons 
(http://www.els.net).
Blaszczyk, M., Mateusz, K., Maksim, K., 
Lukasz, W., Aleksander, D. & Andrzej 
K. (2016). Modeling of Protein-Pep-
tide Interactions Using The CABS-dock 
Web Server for Binding Site Search and 
Flexible Docking. Method. 93, 72-83.
Bruni, L., Albero, G., Serrano, B., Mena, M., 
Gómez, D., Muñoz, J., Bosch, FX. & de 
Sanjosé, S. (2019). ICO/IARC Informa-
tion Centre on HPV and Cancer (HPV 
Information Centre). Summary Report. 
Human Papillomavirus and Related 
Diseases in Indonesia.
Fatima, S. S. & Desu, J. (2014). Proteome 
Analysis and Antigenic Peptide Predic-
tion of Beta Corona Cirus, A Cause of 
MERS. Helix, (5), 590-583.
Fleri, W. (2012). T-Cell epitopes - MHC Class 
I Binding Prediction Tools Description. 
Jurnal Biodjati 4(2):252-262, November 2019 262
Jurnal Biodjati 4(2):252-262, November 2019
http://journal.uinsgd.ac.id/index.php/biodjati
Retrieved from http://help.iedb.org/
entries/21903572-t-cell-epitopes-mhc-
class-ii-binding-prediction-tools-de-
scription.
Fleri, W. (2012). T-Cell epitopes - MHC Class 
II Binding Prediction Tools Description 
IEDB Solutions Center. Retrieved from 
http://help.iedb.org/entries/21903572-t-
cell-epitopes-mhc-class-i-binding-pre-
diction-tools-description.
Gonzalez, A. D., Marcela, L., Myrna, C., 
Lucely, C., Claudia, A. & Eduardo, C. 
(2005). Epigenetics of Cervical Cancer. 
An Overview and Therapeutic Perspec-
tives. Molecular Cancer, 4(38), 1-24.
Kim, Y., Julia, P., Zhanyang, Z., Dorjee, T., 
Peng, W. & Jason, G. (2012). Immune 
Epitope Database Analysis Resource. 
Nucleic Acids Research, 40, 525-530.
Kurcinski, M., Michal, J., Maciej, B., Andrzej, 
K. & Sebastian, K. (2015). CABS-Dock 
Web Server for the Flexible Docking 
of Peptides to Proteins without Prior 
Knowledge of the Binding Site. Nucleic 
Acids Research, 1-6.
Li, B., Xianfang, Z., Chuancui, H. & Yunx-
ia, C. (2015). Human papillomavirus 
Genome-Wide Identification of T-cell 
Epitopes for Peptide Vaccine Develop-
ment Against Cervical Cancer: An Inte-
gration of Computational Analysis and 
Experimental Assay. J Computation 
Biol, 22(10), 962–974.
Morshed, K., Dorota, P., Marcin, S. & Małgor-
zata, P. (2014). Human Papillomavirus 
(HPV) – Structure, Epidemiology and 
Pathogenesis. Otolaryngology Polska. 
Elsevier. pp. 213 – 219.
Sompayrac, L. How the Immune System Work. 
3ed Edition. (2008). Massachussetts: 
Well Publishing.
Taupiqurrohman, O. (2016). Desain dan 
Pengembangan Vaksin Human papillo-
mavirus Tipe 16 Berbasis Epitop Secara 
In Silico. Thesis. Bandung. Universitas 
Padjadjaran.
Taupiqurrohman, O., Yusuf, M., S. Nuswan-
tara, T. & Subroto, T. (2016). Potensi 
Gen Oncoprotein Human Papillomavi-
rus Tipe 16 Sebagai Kandidat Vaksin 
Kanker Serviks. MKB, 48(35), 84– 91.
Vita, R., Laura, Z., Jason, A. G., Hussein, E., 
Ilka, H., Nima & Rohini D. (2010). The 
immune Epitope Database 2.0. Nucleic 
Acid Research, 38, 854-862.
WHO. (2019). Human papillomavirus (HPV) 
and cervical cancer. [Downloaded at 
Agustus 2019]. https://www.who.int/
news-room/fact-sheets/detail/human-pap-
illomavirus-(hpv)-and-cervical-cancer.
